The team’s findings were published on July 23 in the prestigious journal Fluids and Barriers of the CNS. This collaborative effort involved researchers from TTUHSC’s Jerry H. Hodge School of Pharmacy in Amarillo, and the Graduate School of Biomedical Sciences. Helmed by principal investigator and senior author, Dr. Ulrich Bickel, with lead author Ehsan Nozohouri — a TTUHSC graduate research assistant — the study also included contributions from other graduate researchers within the institution. Their combined expertise and innovative methodologies culminated in a transformative understanding of the BBB in the context of Alzheimer’s pathology.

Historically, scholars have debated whether Alzheimer’s disease results in the impairment of the BBB. Traditionally perceived as a protective barrier, the BBB is made up of tightly connected endothelial cells that serve as a gate, determining what enters the brain from the bloodstream. The prevailing theory suggested that the onset of Alzheimer’s could compromise the integrity of this barrier, leading to a situation where harmful compounds could enter the brain and exacerbate the disease.

The implications of this study are profound for the field of Alzheimer’s research. Ehsan Nozohouri elucidated that understanding the integrity of the BBB becomes critical, particularly for drug delivery systems intended to treat Alzheimer’s disease. Since the BBB effectively blocks the majority of medications, revealing its actual condition in Alzheimer’s provides essential insights for future therapeutic strategies.

In their investigation, Nozohouri and his colleagues employed the Tg2576 mouse model, which is well-documented for its propensity to develop amyloid beta plaques synonymous with Alzheimer’s pathology. To probe the integrity of the BBB, the research team injected a harmless test molecule, [¹³C₁₂]sucrose, a compound known for its poor ability to cross the BBB. By utilizing advanced analytical techniques, including liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) and laser microdissection for precise tissue sampling, they meticulously monitored the presence of sucrose in various brain regions.

The results were striking. The examination revealed no significant leakage of sucrose into the brain of either the Alzheimer’s-afflicted Tg2576 mice or their healthy counterparts, at varying ages. This indicates that the BBB is not compromised on a broad scale in this model, and highlights the need for re-evaluation of the theories surrounding BBB permeability in Alzheimer’s disease.

Furthermore, the study suggested that within critical regions of the brain associated with memory and cognitive function, there were no significant differences present between the Alzheimer’s models and healthy mice. This included the examination of tight junction proteins, which function as the “mortar” that holds BBB cells together, again showing largely preserved structures even in proximity to amyloid plaques.

As the scientists contemplate these results, they emphasize that their findings challenge the widespread assumption of extensive BBB leakiness in Alzheimer’s disease. Such revelations could catalyze a paradigm shift in how drugs are designed for effective treatment, as the understanding needs to pivot towards recognizing that the BBB may not universally be compromised in the disease.

Despite the promising nature of the findings from the Tg2576 model, Nozohouri cautioned against a sweeping application of these conclusions to human physiology. The researchers stressed the necessity for additional models that may more accurately reflect human brain responses and the intricacies of Alzheimer’s disease. As the field looks forward, there exist FDA-approved monoclonal antibody treatments showing potential in slowing cognitive decline. Further examination of these therapeutics in relevant models could illuminate pathways whereby localized changes affect drug effectiveness, especially concerning concerns of micromorphological alterations like microhemorrhages.

The team at TTUHSC envisions this research as a starting point for expanded inquiries into the dynamics of Alzheimer’s disease and the BBB. They are committed to further studying how Alzheimer’s may impact the brain’s protective mechanisms and ultimately aspire to hone drug development strategies that can effectively navigate the complexities of the BBB and deliver meaningful therapeutic ramifications to patients suffering from this debilitating condition.

This investigation underscores an urgent need for more refined understanding and innovative strategies in combating Alzheimer’s disease. With the stakes high, researchers are poised to explore the intersections of neuroscience, pharmacology, and therapeutic innovation, all with the overarching goal of improving the lives of those impacted by this formidable disease.

The work done by this team moves us a step closer to unraveling the complexities of Alzheimer’s disease and the mechanisms underpinning its effects on the brain. By shedding light on the actual state of the BBB, they pave the way for future advancements in treatment strategies and foster hope for more effective interventions in the ever-challenging landscape of Alzheimer’s research.

Subject of Research: Animals
Article Title: Assessing blood-brain barrier (BBB) integrity in an Alzheimer’s disease mouse model: is the BBB globally or locally disrupted?
News Publication Date: 23-Jul-2025
Web References: DOI
References: None available
Image Credits: Credit: TTUHSC

Keywords

Biomedical engineering, Clinical medicine, Diseases and disorders, Epidemiology, Health care, Human health, Medical specialties, Pharmaceuticals, Pharmacology.

Historically, assessing the permeability of drugs across the BBB has been complex due to numerous variables, including blood flow dynamics and the binding of drugs to plasma proteins. These factors can substantially influence the rate at which a drug can cross this barrier. Smith and his team recognized the inconsistencies in existing methodologies and aimed to develop a more accurate and systematic approach. Their efforts culminated in a study published in the December 2024 issue of Fluids and Barriers of the CNS. The research article, titled “Brain endothelial permeability, transport, and flow assessed over 10 orders of magnitude using the in situ brain perfusion technique,” provides vital insights that could revolutionize drug delivery strategies for CNS diseases.

The research focused on the in situ brain perfusion technique, a novel method that allows for the measurement of drug permeability under controlled conditions. By carefully manipulating factors influencing BBB permeability, the study aimed to reconcile discrepancies in drug absorption rates documented in previous literature. By evaluating a dataset of 120 different compounds, the research revealed that many CNS drugs could permeate the BBB and achieve equilibrium in the brain in less than 10 minutes. This rapid equilibration rate challenges the established understanding that most CNS drugs have a slow uptake rate.

The team’s findings indicated that a significant number of commonly used CNS drugs, including antidepressants, antipsychotics, and antiepileptic medications, have far higher permeability through the BBB than previously suggested. They observed that for many of these agents, their ability to cross the barrier is as rapid as the blood flow delivering them. This revelation implies that the long-held beliefs about the incapacity of certain drugs to reach effective concentrations in the brain may need a reassessment in light of this new evidence.

In their discussion of these findings, Smith noted the importance of accurate measurement methods, particularly regarding lipophilic drugs – compounds that easily dissolve in fats – as these were often found to exhibit the most rapid uptake. Traditional methods of calculating BBB permeability, such as the brain-to-blood concentration ratio, lacked precision and led to confusion in the field. The expertise demonstrated by Smith and his colleagues in developing a robust modeling system now provides clearer insights into how drugs can effectively penetrate the BBB.

The research also emphasized the role of plasma proteins in drug delivery. For lipophilic agents, these proteins may not only serve as passive carriers but can also actively assist in maintaining higher free drug concentrations in the brain. An example highlighted was Valium, which under conditions of rapid uptake can redistribute from the plasma protein-bound pool to the brain, enabling it to achieve therapeutic levels significantly faster than previously recognized.

This innovative study has far-reaching implications, especially in urgent clinical scenarios where rapid drug action is essential. For instance, the treatment of status epilepticus, characterized by a series of quickly recurring seizures, necessitates immediate intervention to prevent irreversible brain damage. Smith’s team found that a substantial number of agents employed in these emergency treatments exhibited excellent permeability profiles, underscoring the importance of the research in guiding effective therapeutic choices.

The researchers intended to tackle the misconceptions prevalent in the literature regarding barrier permeability. By demonstrating how plasma-bound drugs can significantly contribute to maintaining free concentration levels in the brain, Smith’s work aims to provide a more cohesive understanding within the scientific community. This holistic perspective bolsters the claim that many current CNS drugs have favorable pharmacokinetic properties, allowing them to penetrate the BBB effectively.

Further investigations into the types of compounds that do not readily cross the BBB revealed a broader understanding of drug behavior. The research pointed out that the presence of highly polar or charged species often hampers drug permeability. Additionally, the study provided insights into how certain biological compounds, which are capable of being transported out of the brain by efflux transporters, complicate the landscape of drug delivery across the BBB.

Smith’s comprehensive dataset suggests the established notion that 95-99% of potential drugs are blocked at the BBB might be overstated. His research proposes that the actual percentage could be lower, allowing for greater potential for drug candidates to successfully gain access to the brain.

This study not only enriches the field of pharmacology but also highlights the evolution of scientific understanding regarding the blood-brain barrier. Smith’s extensive career and continuous dedication to unraveling the complexities of CNS permeability standing for over five decades speak volumes about the ongoing advancements sought in this critical area of biomedical research. The future of drug delivery systems feels poised for transformation as the insights from this research disseminate into practical applications across clinical settings.

Looking forward, Smith expressed optimism regarding further advances in understanding the blood-brain barrier and its implications for treating neurological disorders. This comprehensive study stands as testament to the importance of collaboration in scientific research, yielding insights that could reshape methodologies in the field and lead to significant improvements in patient outcomes. As the medical community continues to grapple with the challenges of drug delivery, the work conducted by Smith and his team may very well provide the keys to unlocking new treatment strategies for some of the most challenging CNS disorders.

In conclusion, the collaborative efforts and pioneering methodologies presented in this research are a beacon of hope for clinicians and researchers alike. The tangible improvements in our understanding of drug permeability across the blood-brain barrier may pave the way for the development of more effective therapeutic agents in the near future.

Subject of Research: Blood-brain barrier permeability
Article Title: Brain endothelial permeability, transport, and flow assessed over 10 orders of magnitude using the in situ brain perfusion technique
News Publication Date: 17-Dec-2024
Web References: Link to Article
References: N/A
Image Credits: Credit: TTUHSC

Keywords: Blood-brain barrier, CNS drugs, Drug delivery, Pharmacology, Plasma proteins, Drug permeability, Seizure treatment, Neurological disorders, Antidepressants, Antiepileptics, Lipophilic agents, Therapeutic levels.